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Tissue Phenomics is the discipline of mining tissue images to identify patterns that are related to clinical 
outcome providing potential prognostic and predictive value. This involves the discovery process from 
assay development, image analysis, and data mining to the final interpretation and validation of the 
findings. Importantly, this process is not linear but allows backward steps and optimization loops 
over multiple sub-processes. We provide a detailed description of the Tissue Phenomics methodology 
while exemplifying each step on the application of prostate cancer recurrence prediction. In particular, 
we automatically identified tissue-based biomarkers having significant prognostic value for low- and 
intermediate-risk prostate cancer patients (Gleason scores 6–7b) after radical prostatectomy. We found 
that promising phenes were related to CD8(+) and CD68(+) cells in the microenvironment of cancerous 
glands in combination with the local micro-vascularization. Recurrence prediction based on the selected 
phenes yielded accuracies up to 83% thereby clearly outperforming prediction based on the Gleason 
score. Moreover, we compared different machine learning algorithms to combine the most relevant 
phenes resulting in increased accuracies of 88% for tumor progression prediction. These findings will be 
of potential use for future prognostic tests for prostate cancer patients and provide a proof-of-principle 
of the Tissue Phenomics approach.
Tissue Phenomics is the systematic discovery of quantitative descriptors for functional, morphological and spatial 
patterns in tissue which correlate with disease progression or drug response. It complements genomics which 
links genetic information and disease1 by adding information on protein expression levels, cellular interactions 
and architectures. Using the latest whole slide imaging hardware, advanced multiparametric image analysis, and 
big data knowledge discovery, Tissue Phenomics may supersede the manual discovery of novel scoring algorithms 
in histopathology. Since the extracted quantitative descriptors can be stored in large databases and cross-linked 
with other biomedical knowledge, Tissue Phenomics also stimulates clinical research, improves clinical drug 
development and the treatment of patients. Novel image-based biomarkers, referred to as tissue phenes, leverage 
pathologists’ scientific and clinical insight into the information contained in tissue. Therefore, it has potential to 
impact decisively on medicine in general and on oncology in particular.
Examples of novel tissue- and image-based biomarkers have been described in previous work, e.g. refs2–4. 
While Beck et al.2 followed a hypothesis-free approach, for Galon et al.3 and Caie et al.4 knowledge about a poten-
tial correlation of certain tissue structures and their properties with clinical outcome already existed. However, in 
all three cases quantification and statistical evaluation led to surprising results that could not have been achieved 
by manual approaches. In Galon et al.3 it was known that the immune system responds to tumor tissue, but it was 
not anticipated that the immune response could be described by a relative simple mathematical formalism with 
a high prognostic value. For Caie et al.4 budding tumor cells in the invasive margin of colon cancers were known 
to have a meaning for the prognosis of patients (e.g. refs5,6), but the high prognostic value of big structures of 
buds was discovered only by using Tissue Phenomics. In the work of Beck et al.2 structural features significantly 
associated with survival in breast cancer were discovered in the stroma close to the tumor by quantification and 
data mining in an unbiased data-driven Tissue Phenomics approach.
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Other related approaches identified prognostic image-based biomarkers based on, e.g., nuclear morphometric 
features in male breast cancer7, spatial arrangement patterns of stromal cells in breast cancer8 and of tumor cells in 
oropharyngeal squamous cell carcinomas9, or glandular orientation patterns in prostate cancer10. However, these 
approaches were based on relatively clearly sketched initial hypotheses, therefore operating on specific and tar-
geted feature sets. This naturally limits the ability of discovering novel and unexpected image-based biomarkers 
for creating new biological insights which is a main objective of Tissue Phenomics. For a more general review of 
approaches for predictive modeling in histopathological images see, for example11.
In this study, we used the Tissue Phenomics approach to identify novel prognostic biomarkers for pT2-staged 
prostate cancer patients who underwent radical prostatectomy with negative resection border. Subsequent to sur-
gery those biomarkers support the selection between more aggressive treatment options such as radiation therapy 
and more conservative options such as watchful waiting. The clinical endpoint used in the discovery process was 
the prostate-specific antigen (PSA) recurrence. Since the Gleason grading is of limited prognostic value for low 
and intermediate-risk patients (Gleason score <= 7b)12 we included in our study immune contexture-related 
information such as markers for CD8(+) cytotoxic T-cells as well as CD68(+) M1 and CD163(+) M2 mac-
rophages. Inspired by the Immunoscore for colon cancer patients3 we investigated the spatial relationship of the 
various immune populations within cancer, stromal and benign regions. The comprehensive screening for prog-
nostic signatures based on multi-parametric sets of contextual cell density measurements sets this study apart 
from recent investigations on single aspects of certain cell populations (e.g. ref.13).
Material and Methods
The Tissue Phenomics approach. The core of the Tissue Phenomics methodology is an iterative opti-
mization workflow comprising experimental and lab-related steps such as study design, assay development, tis-
sue acquisition, staining and digitization, as well as advanced image and data analysis for phene discovery and 
optimization. A final validation step ensures the bio-statistical and biomedical validity of the biomarkers repre-
sented by the discovered phenes (see Fig. 1A). In this paper, we use the example application on prostate cancer 
recurrence prediction to describe the Tissue Phenomics workflow (see Fig. 1B). For every step we first provide a 
general description followed by the concrete application example.
Study design and execution. Study design. In the study design process, the general conditions and 
parameters of the study are defined, such as number and type of cases, as well as the type and selection criteria 
of tissue samples. As certain parameters or conditions might turn out to be not optimally chosen throughout the 
Figure 1. The Tissue Phenomics workflow. (A) General workflow: Tissue Phenomics is a Big Data approach for 
quantitative histopathology, spanning from assay development to phene validation based on automated multi-
parametric optimization. (B) Example application: Identification of phenes for improved prognosis for low- and 
intermediate-risk prostate cancer patients after radical prostatectomy. Note that in this example the phene 
validation step is not yet fully covered. (For algorithm descriptions see supplemental material, flow charts).
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progression and evaluation of the study, all parameters are eligible for later optimization regarding the overall 
solution quality through multiple iterations of a feedback loop.
The prostate cancer study included 90 low- and intermediate-risk prostate cancer patients 
(Gleason-Score ≤ 7b, age <= 75 years, staging pT2, resection border R0)14. All patients underwent radical pros-
tatectomy and a follow-up of the patients within a period of 2–118 months was available where 40 patients devel-
oped prostate-specific antigen (PSA) biochemical recurrence, indicating tumor progression (disease-free survival 
mean = 25.8 months, median = 31.5 months), see Table 1. Standard clinical data such as Gleason score, cancer 
stage, pre-operative PSA value, and age did not allow accurate prediction of disease progression as shown by 
survival analysis and Cox regression (see supplemental Figs S1, S2, and Table S1).
The goal of the study was to identify phene candidates providing a reliable prognosis of disease progression 
based on serially cut and immunohistochemically stained tissue sections using biomarkers for epithelial, endothe-
lial, basal, and immune cells. For the ethical approval of the study see end of section Material and Methods below.
Assay definition. A tissue phene can be defined as a quantified characteristic of a structure in formalin-fixed 
paraffin-embedded (FFPE) or fresh frozen tissue sections. In a broader definition, also radiological images of 
tissue can be included, however, in this work we focus on microscopic investigations. The right choice of staining 
methods is critical for the success of phene discovery in the context of a specific application. Relevant criteria are, 
for example, the selection of proteins and genes, and of corresponding probes and stains, robustness of the assay, 
and the deployment model in a clinical environment. In a typical setup for phene discovery, the assay initially 
consists of a defined set of stains which, however, will potentially not all be relevant for answering the biomedical 
question. On the other hand, throughout the data mining process new hypotheses might be generated, suggest-
ing to add other proteins to the assay. Such adaptations can be addressed in multiple optimization iterations of 
the workflow in Fig. 1. Another consideration is the choice between serial sections in brightfield immunohisto-
chemistry or immunofluorescence. Highly multiplexed immunofluorescence may be preferable due to its rich 
information content and perfect spatial alignment, however, more economical brightfield methods may as well 
provide sufficient spatial information and accuracy given recent advances of automatic co-registration approaches 
(see, e.g. refs15–17).
For the prostate cancer study, a set of three dual stains (CK18/p63, CD68/CD163, CD3/CD8) and one single 
stain (CD34) emerged from the Tissue Phenomics optimization by showing relevant prognostic potential regard-
ing cancer recurrence. Other initially involved stains (e.g., CD45RO, CD20) were removed from the phene dis-
covery workflow, as they showed limited relevance for prostate cancer progression. Also, single stains (e.g., CD3, 
CD8) were replaced by dual stains (CD3/CD8). The stains were selected to provide spatial and structural infor-
mation, as well as functional information with respect to the immune status of the tumor. Structural information 
for the annotation of cancerous and non-cancerous tissue was gained from CK18/p63. CK18 visualizes epithelial 
tissue providing a clear outline of the prostate glandular system, while p63 gives information on whether the 
basal membrane enclosing a gland is intact or non-intact. The basal epithelial cells of an intact basal membrane 
express p63, while cells of a corrupted basal membrane lack this protein. Thus, p63 was used as a direct marker for 
separating cancer tissue from non-cancer tissue in prostate. All other stains were selected to provide information 
on the local immune status of the investigated tissue, in particular, to monitor interactions of important players, 
such as CD68/CD163 corresponding to M1 and M2 macrophages, CD3/CD8 expressed by all T-cells (CD3) and 
cytotoxic T-cells (CD8), as well as CD34 visualizing the micro vasculature.
Assay execution and slide scanning. According to the study design and the assay definition tissue is collected, 
fixated, processed, and stained. Highly standardized procedures are recommended for these steps to generate 
relevant and comparable data and facilitate information extraction in the datafication step18. For slide scanning 
high-throughput whole-slide scanners are used allowing a high degree of automation.
In the prostate cancer study consecutive formalin-fixed, paraffin-embedded tissue (FFPET) sections were 
derived from the resected prostate tissue. Immunohistochemistry was performed according to standard proto-
cols using the Ventana Benchmark technology to achieve reproducible and reliable immunohistochemistry test 
results by standardization of every step in preanalytic, analytic, and postanalytic phases19. Whole FFPET sections 
cut at 3 µm were stained with a Ventana Benchmark XT autostainer (Ventana Medical Systems). Details of the 
antibodies and methods employed are given in supplemental Table S2. Slides were counterstained with haema-
toxylin (Ventana). System and isotype controls were included. All sections were imaged using a ZEISS Axio Scan.
Total number of patients 90































Overall follow-up period 2–118 months
Table 1. Properties of the prostate cancer patient cohort.
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Z1 tissue scanner (Carl Zeiss, Jena, Germany) using a 20x objective (resolution 0.22 μm/pixel). At minimum four 
digital RGB whole-slide images per patients with around 100 k × 100 k pixels were acquired (i.e. 1–2 GB per 
image after compression, see supplemental Fig. S3).
Image analysis for tissue datafication. Datafication workflow. The goal of tissue datafication is to extract 
information from digital images providing a set of phene candidates. The typical datafication workflow comprises 
(I) image normalization, (II) structure-of-interest detection, (III) co-registration of consecutive tissue sections, 
(IV) statistical region-based data aggregation and quantification. Note that the order of steps (II) and (III) is of 
relevance only in specific cases, e.g., if the co-registration relies on the detected structures-of-interest or, vice-versa, 
if the structure-of-interest detection in one tissue section makes use of structures from another tissue section.
The datafication workflow for the prostate cancer study is shown in Fig. 2. First, image co-registration was 
performed on the digitized tissue slides, followed by the detection of structures predefined from domain knowl-
edge as being relevant (e.g., cell nuclei, glands, vessel segments). Next, the extracted information was combined in 
hyper-spectral heatmaps using the geometric transformation parameters obtained by co-registration, and finally, 
the heatmaps were further processed, for example, to identify cancerous vs. non-cancerous tissue and quantified 
considering the identified regions-of-interest (ROIs). All steps are described in the following sections.
 (1) Image normalization
In histopathological image analysis, normalization often is required due to the relatively large variability of 
the data. Stain variations are caused, for example, by use of different scanners or staining protocols, varying 
stain intensities or tissue slice thickness. Consequently, a broad variety of normalization approaches have 
been developed in this field. Basic general purpose techniques are, for example, based on the image histo-
gram and perform histogram normalization (min-max normalization), histogram equalization, or map-
ping of histograms (by transferring gray value means and standard deviations)20 within each color channel. 
However, such techniques are based on the assumption that the content of all images to be normalized is 
relatively similar, and thus, histograms are generally comparable. More advanced approaches are based 
on color deconvolution21, and use, for example, singular value decomposition22, independent component 
analysis23 or blind color decomposition24. For immunohistochemical stains, in particular, approaches 
based on non-negative matrix factorization (NMF)25 have been shown to be successful, such as sparse 
NMF26 or structure-preserving color normalization27. For a comparison of stain normalization approaches 
see, e.g. refs28,29. In the prostate cancer example a specific stain normalization step was not required since 
our methods for segmentation and image registration inherently account for stain variations and the data 
variability was generally low. In related work we used, e.g., histogram equalization30.
 (2) Structure-of-interest detection and classification
Hierarchical structure detection using CNL: A key challenge of datafication is the automated detection of 
relevant structures in the images such as cell nuclei, cells, glands or other structural units, or different tissue 
architectures. The heterogeneity and variability of tissue types and structures, the section level and thick-
ness, as well as staining issues are major challenges. Therefore, correct identification of structures typically 
requires incorporating domain knowledge on the structures-of-interest, for example, using model-based 
approaches with implicit knowledge representation or by explicitly formulating selection criteria (see, e.g. 
refs31,32). An effective approach to formulate object detection algorithms and generate object hierarchies 
Figure 2. Datafication workflow for the prostate cancer project.
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while incorporating domain knowledge is the Cognition Network Language (CNL), a visual scripting 
language developed to implement the Cognition Network Technology (CNT33).
In CNL, object detection is formulated as an iterative optimization process, grouping pixels to objects and 
objects to object groups, and refining groups by re-segmentation, group merging or splitting. Alternation 
of local segmentation operations with local classification steps allows successive extraction of information 
while optimizing the state of the network of objects until all structures-of-interest are correctly represent-
ed. CNL supports a hierarchical organization of structures using “consists-of ” relations (e.g., tissue, tumor, 
viable tumor, tumor cells, cell membrane, see Fig. 3). The network provides context information for the 
contained structures which is used to support difficult or ambiguous decisions. Explicit expert knowledge 
characterizing structures-of-interest is included, e.g., using fuzzy logic memberships functions34–36. For 
more complex cases where the relevant structure descriptors cannot be explicitly formulated, models with 
implicit knowledge representation can be incorporated using machine learning methods for classification 
such as Random Forests or Deep Learning algorithms.
In our prostate cancer example the datafication step involved detection of marker-positive cells in sections 
stained for CD3/CD8 and CD68/CD163, detection and classification of glands in CK18/p63, as well as 
detection of vessel segments in CD34 (Fig. 2). All object detection approaches were developed in the CNL 
programming framework.
Gland and vessel segment detection: In images stained for CK18 glands were characterized by a brown-
stained cell layer surrounding glandular lumina (see Fig. 4A). For gland segmentation, first luminal 
epithelial cells were detected based on a generic brown stain detection. Next, luminal region candidates 
were identified based on a fixed brightness threshold and morphological operations, and filtered with 
respect to the existence of neighboring epithelial cells taking advantage of the image object network. Thus, 
only luminal regions surrounded by epithelial cells were identified as glandular lumen. The resulting gland 
candidates were refined and split into neighboring glands using morphological operations and network 
relations. To classify glands into healthy glands (with intact basal membrane) and cancerous glands (with 
non-intact basal membrane), a segmentation of the red-stained p63(+) cell nuclei was performed and the 
CNL network’s neighborhood relations of glands and p63(+) cells were used for gland classification (Fig. 
4). For algorithm details see supplemental material, flow chart 1.
Vessel segment detection was performed using a similar brown stain detection method as used for the 
luminal epithelial cells. The detected segments were post-processed using morphological operations to 
derive meaningful vessel objects.
Cell and cell nucleus detection: The approach applied for cell detection37 is based on the assumption that 
cell objects underlie a certain morphological consistency and a few well-differentiated representatives of the 
objects are present in the images. First, well-differentiated objects are automatically extracted based on mor-
phological criteria (size, shape, color constraints), selecting clear and unambiguous cases only from a subset 
of representative image sections. Second, the detected objects are used to learn the visual appearance of (I) 
the current image set (with respect to staining, cutting, and digitization), and (II) the characteristic visual 
context of the objects-of-interest which also applies for low-differentiated objects (e.g., clustered nuclei). The 
visual context model is based on Random Forests using Long-Range features38. Finally, the model is applied 
to the whole-slide images to predict cell candidates, which are filtered and refined resulting in a robust 
segmentation. Note that no manual annotation is required with this approach. For algorithm details see sup-
plemental material, flow chart 2. In the prostate cancer study we used the cell detection to identify CD68(+) 
and CD163(+) cells, corresponding to tumor-associated macrophages (M1 and M2, respectively), as well as 
CD3(+) and CD8(+)-expressing T-cells, and all marker-negative cell nuclei (see Sect. Results below).
Figure 3. Schematic representation of the network of relevant objects detected in CK18/p63 tissue slides with 
hierarchical “consists-of ” relations (in blue), and non-hierarchical “is-neighbor-of ” relations (in orange).
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 (3) Image co-registration
To jointly study different structural or functional entities (e.g., different cell types) serial sections are 
stained with a panel of multiple biomarkers. Co-registration of serial sections (virtual multiplexing) 
enables quantification of spatial relations between objects detected in different sections. However, for 
immunohistochemically stained sections co-registration is particularly challenging since the characteris-
tics of different stains are typically highly dissimilar for different stains and purely intensity-based methods 
are not directly applicable (multi-modal registration problem). To deal with multi-modality, macroscopic 
landmarks with semantic meaning, such as previously detected vessels or glands which are similar in pos-
sibly many sections can be used for alignment. Other challenges are artifacts such as tissue folds, ruptured 
tissue or lacking tissue parts, mirrored tissue sections resulting from flipping during the slide preparation, 
or non-consecutive sections leading to a lack of corresponding structures between sections (for an example 
see Fig. 5, panel D vs. panels A-C).
In the prostate cancer study a set of four serial tissue sections per patient was used. These sections were 
dual stained with quite dissimilar color and intensity ranges (Fig. 5). Thus, a multi-modal automatic 
co-registration approach was used (17 with local alignment module by microDimensions, Munich, Germa-
ny). With this approach, first, all tissue regions in all sections were automatically detected and a global rigid 
registration was performed for initial coarse alignment. To tackle the multi-modality problem, the images 
were normalized using a minimum intensity projection of the RGB image color channels and subsequent 
intensity inversion which allows using an intensity-based objective function (normalized cross-correla-
tion) for optimizing the image alignment. After global alignment, co-registration was performed in a hier-
archical fashion by splitting tissue regions into local patches and repeating the co-registration in sub-re-
gions at multiple resolutions. Finally, landmarks encoding local rigid transformations were generated at 
the local patch region centers for the given target resolution (Fig. 5, green circles). For algorithm details see 
supplemental material, flow chart 3.
 (4) Data aggregation and quantification
The detected structures, their mutual relations, as well as the transformation parameters for spatial 
alignment are the basis for the aggregation and quantification step. The quality and the significance of the 
extracted data naturally depends on the quality of such previous steps, and thus, quality control is required 
prior to the quantification step. Next, a multitude of automated measurements of different complexity, and 
based on different types of object relations can be extracted. Object relations are characterized by the type, 
hierarchy level, and image section of the respective objects as well as by the type of combination, i.e. within 
the same or between different object types, hierarchy levels or image sections. This involves, for example, 
measurements of single structures of the same type and hierarchy level within the same section, such as 
cell morphology, cell staining intensity with respect to a specific marker, or region size, non-hierarchical 
relational characteristics between different object types within or between sections, such as the average 
distance of type 1 cells to their four nearest neighbors of type 2 cells. Also, hierarchical relational character-
istics within or between sections, such as the number of nucleoli inside a nucleus, or the number of specific 
cell types inside the tumor region can be involved.
A major challenge is to reduce the enormous number of possibilities to combine measurements for phene 
candidates in a meaningful way. For statistical reasons, the number of phene candidates needs to be limited 
compared to the number of cases in the study cohort. For efficient local quantification and visualiza-
tion, measurements from different sections can be aggregated in lower spatial resolution representations 
(typically 100 microns per pixel), so called hyper-spectral heatmaps39. The term hyper-spectral refers to 
the large number of potential measurements, where each spectral channel of the heatmap represents one 
measurement (see Fig. 6A). Image analysis is used for detecting regions-of-interest (ROIs, see Fig. 6B) 
and meaningful structures in such hyper-spectral heatmap images, for example, unsupervised or knowl-
edge-based segmentation and classification. Measures derived based on heatmap regions provide addition-
al phene candidates.
Figure 4. Illustration of the algorithm for gland segmentation. (A) CK18/p63 raw image, (B) segmentation 
of lumina (yellow) and p63(+) cells (magenta), (C) whole gland segmentation and classification into healthy 
(green) and cancerous (red) glands according to the existence of neighboring p63(+) cells.
www.nature.com/scientificreports/
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In the prostate study we extracted measurements from all available stains. First, ROIs were defined based 
on the classified glands as regions containing primarily cancerous glands, regions containing healthy 
glands, and the remaining tissue regions, referred to as stroma (including stroma and other structures). 
Using morphological operations (opening, closing40) the identified regions were smoothed, and by dilating 
the tumor regions into the stroma we derived the close and wider tumor microenvironment with a width 
of 112.5 µm and 225 µm, respectively (Fig. 6B: light red and orange), as well as the tumor border defined as 
a region reaching equally far to the inside and to the outside of the tumor region (total width 112.5 µm, not 
shown in Fig. 6B). Next, we extracted quantitative information for each ROI, such as (I) region size, (II) 
absolute numbers of CD68(+), CD163(+), CD3(+), CD8(+), and CD34(+) cells per region, (III) average 
distances of all combinations of positive cells using 4 and 8 nearest neighboring cells (e.g., average distance 
of CD68(+) to their four nearest neighbors of type CD34(+)), (IV) distribution patterns of cancerous and 
healthy glands of different sizes41. Using region sizes (I) and absolute numbers (II) we also determined cell 
densities within each ROI. For algorithm details see supplemental material, flow chart 4.
Data mining for Phene discovery. The raw measurements derived in the datafication workflow can be 
further processed and combined to enable more complex phenes. Relational combinations are used to pro-
vide all types of normalizations, such as area densities of marker-positive cells, percentages of marker-positive 
cells, and relations of positive cells of different types within the same or different ROIs. Moreover, other types of 
Figure 5. Co-registration example for a representative image region with four differently stained sections: 
(A) CK18/p63, (B) CD68/CD163, (C) CD34, and (D) CD3/CD8. Green circles highlight 12 corresponding 
landmarks which are used for spatial alignment. Here the tissue sections (A), (B), and (C) are relatively close, 
i.e. the gland structures are similar whereas section (D) seems to be more distant as the glandular structures are 
less similar.
www.nature.com/scientificreports/
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mathematical functions can be used to combine the extracted measurements in a meaningful way, where previous 
knowledge on expected relations may be integrated. However, note that the more complex the combinations of 
measurements the higher the risk of overfitting in the phene discovery step, and the more difficult the interpre-
tation of the results. To further enrich the set of extracted phene candidates the image-based measurements can 
also be combined with other data types such as clinical measurements from blood samples or radiological tumor 
classification (TNM-classification), patient data (e.g., age, sex, weight), or gene expression data. Since phenotypes 
are functionally related to genotypes, enriching phene candidates with genomic or proteomic information offers 
potential to further increase the quality of their prognostic or predictive value. To facilitate the integration of mul-
tiple heterogeneous data sources to a single homogeneous dataset per individual, ontologies provide a common 
vocabulary and help bridging between different disciplines42. Moreover, Tissue Phenomics studies on prognostic 
and predictive phenes require knowledge on the disease progression, such as disease-free survival time (DFS), 
overall survival time (OS) or response to a certain type of therapy, which often resides in heterogeneous databases 
and needs to be linked to the images. Flexible bioinformatics software tools enable the cross-referencing using 
high-level scripting languages such as R43,44 or Cognition Network Language (see above).
The phene discovery process identifies a subset of phenes out of the pool of candidates which exhibit the best 
correlation to the clinical endpoints. The selection is performed by optimizing the quality of the solution for the 
biomedical question considering robustness while avoiding overfitting, and taking into account clinical applica-
bility as well as economic constraints. To this end, machine learning techniques are used such as feature selection, 
supervised and unsupervised learning (e.g., clustering), and multi-parametric optimization of stratification or 
prediction models. The stratification quality typically is measured by Kaplan-Meier statistics such as the log-rank 
test significance and hazard ratio. As a core component of the Tissue Phenomics approach the optimization can 
loop back (Fig. 1) changing the parameters of the datafication process or creating variations of promising phene 
candidates to enable the evolution of potentially more discriminative phenes.
Phene candidate processing in the prostate cancer study involved all types of relational combinations within 
the same or different ROIs and sections. Additional data sources were not included, since one particular goal of 
the study was to provide improved prognostic markers that are purely image-based and complement the standard 
features used for prognosis by pathologists (e.g., PSA value, pT staging, Gleason score, age). Phene discovery 
was done by ranking the extracted phene candidates according to their relevance by systematically testing the 
stratification performance regarding the clinical endpoint disease-free survival time (DFS) with the event PSA 
recurrence (indicating tumor progression). For each phene candidate we optimized a threshold for classifying 
patients regarding the event (tumor progression/non-progression) by iterating the threshold values in the interval 
between the medians of the two event classes (using the known patient outcome data). In each iteration a log-rank 
test was performed and the classification accuracy was computed as the fraction of correctly classified patients. 
The threshold minimizing the log-rank test p-value while maximizing the classification accuracy was selected 
as the optimum (see, e.g. refs45). Finally, all phene candidates were ranked regarding their optimal classification 
accuracies and p-values. The top-ranking phenes with their optimized thresholds provided basic uni-variate clas-
sifiers (Fig. 7).
Figure 6. Heatmaps aggregating data on a lower spatial resolution. (A) Hyperspectral heatmap with 6 channels: 
average distance CD163(+) to CD68(+) macrophages (red) and vice versa (violet), CD34(+) vessel density 
(green), average distance of vessels to CD163(+) macrophages (blue), average distance of vessels to CD68(+) 
macrophages (green), tumor glands (area percentage, red), (B) heatmap with ROIs generated based on the 
structure-of-interest detection of healthy and cancerous glands and morphological operations on the heatmap 
level with tumor gland regions (red), tight tumor border 1 (dark orange), wider tumor border 2 (bright orange), 
healthy gland regions (green), stroma regions (light blue), and background or discarded border (gray).
www.nature.com/scientificreports/
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However, given the large number of around 700 phene candidates and the limited number of n = 90 patients 
this method is prone to overfitting. Therefore, we performed leave-one-out cross validation in the threshold opti-
mization and ranking procedure, where in n iterations n − 1 samples were used for training and prediction was 
done on the one left-out sample per iteration, thereby successively predicting all cases. This procedure resulted in 
more realistic performance estimates and favored phenes that are robust with respect to small alterations of the 
data set. Therefore, the number of occurrences at the top of the per-fold ranked lists was quantified for each candi-
date over all cross validation folds, providing an estimate of the candidate’s robustness. Phene ranks were assigned 
based on the classification accuracy on the test folds, aggregated over all cross validation folds per phene candi-
date as well as on the robustness in terms of top-5 occurrences. Based on the final ranking we selected the top k 
phenes from the ranked phene list. For example, Fig. 8 shows the Kaplan-Meier plot for the top-ranking phene 
applied as a uni-variate classifier using the average optimal threshold over all cross validation folds. To find the 
number of statistically relevant candidates k, we performed feature selection based on multiple-testing correction 
on the p-values derived from the log-rank test on the cross-validated aggregated predictions. To this end, first, 
poor-performing candidates with cross-validated accuracies ≤50% were removed from the list of candidates. 
Next, we performed multiple-testing correction using Bonferroni correction, a family-wise error rate method 
(FWER46), and a method controlling the false discovery rate (FDR47). Since Bonferroni correction assumes inde-
pendence of the feature values we first applied a correlation filter which removes strongly correlated features in an 
iterative procedure (maximum allowed absolute correlation MAC < 0.75). Using the corrected significance levels 
αcorr, smaller sets of relevant phenes with p-values < αcorr were obtained. For example, using the Holm-Bonferroni 
correction46 20 significant phenes were identified (supplemental Table S3).
Figure 7. Phene candidate ranking based on Kaplan-Meier statistics (log-rank test) and classification accuracy. 
(A) Boxplot of one example phene candidate for the patient group showing tumor progression (green) and for 
the patient group with non-progression (blue), the bold horizontal line inside each box represents the group 
median. For threshold optimization values in the range between the medians are tested (red horizontal line). 
(B) Log-rank test p-values for different thresholds where the relevant local minimum is marked (red circle). (C) 
Corresponding list of p-values and accuracies for different thresholds as used for optimization.
Figure 8. (Left) Kaplan-Meier plot for the prediction based on the top-ranking phene candidate ratio of 
CD8(+) and CD34(+) in tumor microenvironment using a leave-one-out cross validation scheme (log-rank 
test on aggregated prediction p < 3.05·10−7, prediction accuracy 83.3%). (Right) Confusion matrix where rows 
provide the true class and columns the predicted class (0: non-progression, 1: progression). (Note that for some 
patients with DFS times of up to 36 month the exact disease recurrence dates were not available and only the 
approximated DFS time of 36 month could be used, leading to the event aggregation at 36 month in the plot).
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To further reduce the number of relevant phene candidates we performed feature subset selection on the 
relevant phenes in supplemental Table S3 using the supervised classification method CART (Classification and 
regression trees48). CART training builds a decision tree of a given depth, where for each individual branch of 
the tree the feature providing the best class separation is selected from the list of features. Thus, if the number 
of decisions in the tree is smaller than the number of available features, the classifier performs automatic feature 
subset selection. In a leave-one-out cross validation procedure we aggregated the frequencies of phenes being 
selected by CART training over all cross validation folds. Table 2 provides the resulting list of 8 phenes that have 
been selected in at least one cross validation fold along with the previously determined average threshold, perfor-
mance and the selection count (for interpretation of the phene names see Table 3). The relevance of the selected 
top-ranking phenes was additionally approved by Cox regression analysis (supplemental Table S4). For algorithm 
details see supplemental material, flow chart 5.
The selected phene sets were employed for multi-variate stratification using supervised or unsupervised learn-
ing methods (see Sect. Results below). Figure 9, for example, shows the result of unsupervised hierarchical clus-
tering on the 20 selected phenes (after z-score normalization) similar as used in genomics data analysis49.
To test the significance of the highest yielded accuracies and p-values reflecting the importance of the 
top-ranking phene candidates, we performed permutation tests. Feature vectors (i.e. the individual phene candi-
date values) of all patients were randomly shuffled against their clinical outcome data (DFS, event) and the phene 
candidate ranking was performed as described above. Shuffling and ranking was repeated 100 times generating 
a distribution of top-ranking accuracies and p-values for the permuted data sets (meanaccuracy = 0.68, std devaccu-
racy = 0.02, meanpValue = 0.01, std devpValue = 0.02). The approximated probability of yielding similar or higher accu-
racies for the permuted set compared to the unpermuted data turned out to be zero for most of the selected 20 
phenes (15 out of 20) emphasizing the significance of the top-ranking phenes (permutation test p-value < 0.05 for 
13 top ranking phenes). (Note that we did not use cross validation when generating the permutation distribution.) 
For a general summary of feature selection methods in the context of Genomics and Proteomics see, e.g. ref.50.
Model: tumor non-progression if
ACC P-VAL NUMPhene OP THR
1 RATIO #CD8_border1 TO #CD34_border1 >= 0.10 0.83 3.05e-007 86
2 DIST CD68 TO CD34 IN nonIntact >= 75.70 0.82 2.89e-008 90
3 CORR Haralick on intact & non-intact glands < 0.09 0.82 4.68e-006 85
4 RATIO #CD8_nonIntact TO #CD163_nonIntact >= 0.40 0.74 0.00021 4
5 DIST CD3 TO CD8 IN border2 < 99.45 0.73 9.71e-005 2
6 RATIO #CD68_border2 TO #CD34_border1 >= 0.04 0.76 1.84e-005 1
7 DIST CD3 TO CD8 IN innerBorder < 98.69 0.74 0.00047 1
8 RATIO #CD8_ws TO #CD3_ws >= 0.73 0.72 7.80e-005 1
Table 2. Subset of significant phenes resulting from feature selection after multiple-testing correction 
(supplemental Table S3) using CART in a cross validation scheme. Column Phene provides a short definition 
(for interpretation of the phene names see table panel B), which together with the operator OP and the 
threshold THR defines the model for classifying patients as tumor non-progression (distances are given in µm). 
ACC provides the cross-validated accuracy and NUM represents the frequency each phene candidate has been 
selected by the CART classifier over all cross validation folds. For interpretation of the phene names see Table 3.
Operation Argument 1 Separator Argument 2 Separator Location
Examples
RATIO #CD8_border2 TO #CD163_border1
DIST CD163 TO CD8 IN intact
DENSITY CD34 IN stroma
Operations Locations
• RATIO: ratio of arguments • intact: healthy gland regions
• DIST: average distance from object of type Argument 1 
to its four nearest neighbors of type Argument 2 • non-intact: cancerous gland regions
• DENSITY: number of pixels of type Argument 1 divided 
by region size (in number of pixels) of region Location
• stroma: stroma regions
• innerBorder: tumor border reaching to the inside 
and to the outside (56 µm in each direction)
• CORR Haralick: gland co-occurrence features 
quantifying the joint appearance of different gland types
• border1: tight tumor border (112.5 µm)
• border2: wider tumor border (225 µm)
• ws: whole slide including all regions excluding 
non-tissue background
Arguments
• biomarker for which the considered objects are positive
• #biomarker_location: absolute number of objects within the given region (see location)
Table 3. Naming conventions explaining how to interpret phene names.
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Phene validation. Once the best-performing phenes are selected and before they can be considered for clin-
ical evaluation, a comprehensive validation of the discovered phenes is inevitable. It is particularly important to 
prove the relevance of such phenes for independent patient cohorts from different sites with potentially different 
cutting and staining protocols, as well as different slide scanning routines and scanners. Besides, the discovered 
phenes need to be interpreted and validated using domain knowledge from other studies. Finally, dedicated clinical 
studies can be performed to prove the relevance and significance of the identified tissue-based prognostic phenes.
Figure 9. Heatmaps of 20 phene candidates with significant log-rank test results for the stratification of patients 
with respect to tumor progression (blue) and tumor non-progression (red) using Holm-Bonferroni correction. 
(A) Rows sorted by clinical endpoint, (B) rows sorted by clustering, the arrows mark the two main clusters used 
for classification. (For interpretation of the phene names see Table 3).
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In the prostate study, phene validation so far has been addressed by literature research where we identified studies 
supporting the found hypotheses (see section Discussion). However, a validation study on unseen data from a sep-
arate clinical site needs to be performed as a next step. In the light of slow prostate cancer progression, a prospective 
study using the disease-free survival as a clinical endpoint is challenging in terms of study time and resources.
Data availability. The datasets generated during and/or analyzed during the current study are not publicly 
available due to ongoing work on the data analysis but are available from the corresponding author on reasonable 
request.
Ethical approval. The current study was approved by the Ethics Committee of the Medical Faculty of the 
Ludwig Maximilians University (LMU), Munich, Germany, and the need for consent was waived by the institu-
tional ethics committee (Eu Nr 099-14). Prostate cancer specimens from patients that underwent surgical resec-
tion at the LMU were drawn from the archives of the Institute of Pathology. All tumor tissue used was leftover 
material that had initially been collected for histopathological diagnostics and all diagnostic procedures had 
already been fully completed when samples were retrieved for the study. All patient data were fully anonymized, 
and the study was performed according to the standards set in the Declaration of Helsinki 1975. Authors were 
blinded for clinical information during experimental analysis.
Experimental Results
Segmentation and co-registration performance. The accuracy of the cell segmentation has been eval-
uated on a large set of different types of images elsewhere37, and it turned out that the approach yields an average 
nucleus segmentation accuracy of 78% measured over different IHC stains. For the images analyzed in this work 
we performed qualitative assessment of the segmentation accuracy by visual inspection. In all inspected cases 
a sufficiently high segmentation accuracy was observed (see Fig. 10A–D). The accuracy of the gland and vessel 
segmentation was approved by visual inspection as well. For exemplary results see Fig. 4A,C and Fig. 10E,F, 
respectively.
For a performance evaluation of the co-registration approach see17. Since the quality of the co-registration 
naturally depends on the integrity of each tissue section, as well as on the cutting distance of the physical sections 
we inspected all co-registration results and corrected errors where necessary (whole slide flips or larger displace-
ments). Overall, such manual corrections were required only for three out of 90 processed cases.
Phene discovery. Phene ranking and subset selection. Using the phene ranking and selection approach 
described above we obtained a list of 20 significant phene candidates (supplemental Table S3) by applying the 
Holm-Bonferroni-corrected significance level α = 0.05 after filtering for extremely low accuracies (<50%) and 
strongly correlated candidates (r > 0.75). In addition, we obtained a smaller subset of 8 phene candidates (Table 2) 
using CART feature selection.
Patient stratification performance. Uni-variate stratification: The most direct approach to apply the selected 
phenes for patient stratification is using uni-variate classification, that is, patients are stratified based on a single 
phene with a threshold optimized on the training set of patients with known clinical outcome (as described 
above). Figure 11 provides the Kaplan-Meier plots along with the accuracies and confusion matrices for 
uni-variate stratification using leave-one-out cross validation for the top-3-ranking phenes given in Table 2 (see 
supplemental Fig. S4 for all corresponding Kaplan-Meier plots). As can be seen in the first row of Fig. 11 the 
top-ranking phene “RATIO #CD8_border1 TO #CD34_border1” yields a highly sensitive stratification as shown 
by the Kaplan-Meier plot, with only 3 false negative and 12 false positive predictions (for interpretation of the 
phene names see Table 3).
Multi-variate stratification: More complex models for patient stratification combine multiple phenes, for 
example, using unsupervised or supervised classifiers. Here we compared the stratification performance for one 
unsupervised and six different supervised classification methods using the selected sets of significant phenes as 
presented in Table 2 and supplemental Table S3. In particular, we used hierarchical clustering51, Bayes classifiers, 
CART classifiers (depth = 2)48, k-nearest neighbor classifiers (KNN with k = 5), linear predictor models, and 
support vector machines52 with linear and radial basis function kernels.
In case of the unsupervised hierarchical clustering we did not use cross validation since clustering operates 
on the feature values only without considering the class labels. To obtain predictions the clustering tree result-
ing from stepwise bottom-up merging of similar clusters (distance measure: 1-Pearson correlation48) was cut 
after the top-most branching (see dendrograms in Figs 9 and 12), thereby assigning each patient to one of the 
two main clusters. The obtained clustering corresponds very well with the true endpoint tumor progression/
non-progression as can be seen in Figs 9B and 12B, and yields overall accuracies of 84% (log-rank test p < 1.25e-
007) for the phene set identified by Holm-Bonferroni correction (supplemental Table S3), and 87% (log-rank 
test p < 2.14e-008) for the phene set from subsequent CART feature selection (Table 2). Note that we obtained 
higher accuracies for the smaller phene set, suggesting that using more candidates does not provide additional 
discriminatory power.
All supervised classification methods have been tested in a leave-one-out cross validation framework and we 
computed the Kaplan-Meier statistics (log-rank test) for the resulting aggregated set of predictions. The classi-
fication results as well as the Kaplan-Meier plots and statistics for all studied supervised classifiers are provided 
in Fig. 13 and supplemental Figure S5 along with the result of the unsupervised clustering method. It turned out 
that for the multi-variate stratification we generally yield higher accuracies of 81% to 88% than for the uni-variate 
stratification with accuracies of 80% to 84%, and highly significant log-rank test p-values for all tested classifi-
ers (2.69e-010 to 2.46e-005). For the larger set of 20 phenes the top-performing classifiers were the k-nearest 
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neighbor classifier (k = 5) (88%) and support vector machines, where the linear kernel (87%) performed slightly 
better than the radial basis function (rbf) kernel (86%). For the smaller set of 8 phenes the linear predictor per-
formed best (88%) closely followed by support vector machines with linear kernel (87%) and the unsupervised 
hierarchical clustering (87%). Thus, the larger set did not provide additional relevant information as compared to 
the reduced set which offered sufficient discriminatory power for yielding similar accuracies. However, further 
reducing the number of selected phenes led to a decrease of accuracies (data not shown). In conclusion, we found 
the reduced set of 8 phenes selected in the described multi-stage procedure provided the most relevant phenes 
yielding the highest accuracies by multi-variate stratification. Among the top-performing classifiers the support 
vector machines with linear kernel performed very well on both phene sets.
Figure 10. Automatic segmentation results with detection of cells, cell nuclei, and vessel structures. (A) CD68/
CD163 raw image and (B) segmentation result with CD68(+) M1 macrophages (blue overlay), CD163(+) 
M2 macrophages (green overlay), and negative cell nuclei (orange overlay), (C) CD3/CD8 raw image and (D) 
segmentation result with CD3(+)CD8(−) T-cells (magenta overlay), CD8(+) cytotoxic T-cells (green overlay), 
and negative cell nuclei (orange overlay), (E) CD34 raw image and (F) segmentation result with vessel structures 
(red overlay).
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Discussion
For many decades, the microscopic investigation of tumor tissue has been the basis and gold standard for cancer 
diagnosis and treatment, putting the pathologist close to patient care by giving essential guidance for treatment 
decisions. Extracting information from tissue in histopathology often is still predominantly a manual process 
performed by expert pathologists. This process to a certain degree is subjective and depends on the personal 
experience of each pathologist, it is rather qualitative than quantitative, and of limited repeatability as the consid-
erable variability in histological grading among pathologists exemplifies. Moreover, conventional histopathology 
currently does not allow systematic extraction of the rich information residing in tissue sections. The histological 
section represents the complex phenotype in a solid way and as Caie et al53. pointed out, the entirety of DNA, 
RNA, proteome and metabolome are all blended into a topologically ordered and preserved morphological integ-
rity. Therefore, the transition from a more descriptive to a strictly quantitative discipline being the core objective 
Figure 11. Result for uni-variate stratification with cross validation using the top-3-ranking significant phenes 
in Table 2. The Kaplan-Meier plots show groups “non-progression” (green) versus “progression” (blue) as 
predicted, with the events corresponding to true tumor progression state. X-axis: disease-free survival time 
(DFS) in month, y-axis: disease-free survival probability. The provided accuracies and p-values are obtained 
by aggregating the test set predictions in a leave-one-out cross validation. The box plots visualize the respective 
distributions for each phene. In the confusion matrices rows provide the true class and columns the predicted 
class (0: non-progression, 1: progression). (Note that for some patients with DFS times of up to 36 month the 
exact disease recurrence dates were not available and only the approximated DFS time of 36 month could be 
used, leading to the event aggregation at 36 month in the plot).
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of modern histopathology, is clearly worthwhile to pursue. This will allow the extraction of large amounts of 
tissue-derived data from many patients, enabling the creation of unprecedented knowledge through statistical 
evaluations and improving patient treatment.
Conventional approaches such as H&E-based morphological assessment have been increasingly comple-
mented by proteomic and genetic methods, mainly through immunohistochemistry (IHC) and in situ hybridiza-
tion. Genomic studies, although not providing microscopic spatial resolution, started to add value by furnishing 
Figure 12. Heatmaps of 8 phene candidates with significant log-rank test results for the stratification of patients 
with respect to tumor progression (blue) and non-progression (red) using Holm-Bonferroni correction and 
CART-based feature selection. (A) Rows sorted by clinical endpoint, (B) rows sorted by hierarchical clustering, 
the arrows mark the two main clusters used for classification. (For interpretation of the phene names see Table 3).
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rich genetic fingerprints. Several successful attempts have been developed to understand cancer determinants in 
tissue-based genomics with platform technologies such as qPCR and next-generation sequencing. The impor-
tance of genomics in oncology is natural and appears evident as cancer is a genetic disease driven by specific 
genetic mutations. In a number of cases correlations between gene mutations and diseases have been identified 
and associated diagnostic tests have been established54,55. However, today only limited parts of available data are 
of known clinical relevance and are actually used for diagnostic or therapeutic decision-making. Tumors are 
known to be heterogeneous and many different mutations or wild-type gene expression-related features occur 
that might affect patient outcome. Also, the tumor and its microenvironment are characterized by spatial patterns, 
such as the arrangement of cells involved in the interaction of the immune system with the tumor, which cannot 
be adequately characterized by genomic approaches yet is known to be highly relevant for prognosis56. Even 
before the first human genome was fully sequenced, it became obvious that hopes and salvation expectations 
projected onto the emerging field of genomics would be challenging to fulfill.
The concept of the phene, coined a century ago, gained novel significance after being overshadowed by genetic 
approaches for years. An independent discipline named phenomics was postulated to help elucidate the physio-
logical hierarchies leading from genetic traits to clinical endpoints57. A decade later, it was understood that the 
systematic study of phenotypes in relevant biological contexts would be “critically important to provide traction 
for biomedical advances in the post-genomic era”58. Comprehensive phenotyping addresses complexity on dif-
ferent scales: From transcriptomics and epigenomics over proteomics to high-throughput assays of cell cultures 
biological entities of increasing hierarchical complexity are assessed systematically59. However, these approaches 
are compromised by methodological challenges. Performing phenomics on a large scale is an intrinsically 
multi-dimensional problem, because the phenome is highly dynamic. It is influenced by a multitude of factors 
from post-translational modifications to high-level environmental stimuli. Approaches like proteomics, capturing 
temporally highly focused snapshots of multifactorial biological processes, are limited in their transferability and 
significance. In general, the gigantic molecular network that acts between the genome and the unfolding of tissue 
structures with all their properties is still not fully understood. Tissue Phenomics provides a systematic way of 
knowledge discovery thereby contributing to fill this knowledge gap.
Figure 13. Performance evaluation of multi-variate stratification using different types of classifiers with the 
subset of 8 significant phenes selected using the FWER method of Holm-Bonferroni followed by CART-feature 
selection (Table 2). The Kaplan-Meier plots show groups “non-progression” (green) versus “progression” (blue) 
as predicted, with the events corresponding to true tumor progression. X-axis: disease-free survival time (DFS) 
in month, y-axis: disease-free survival probability. In the confusion matrices rows provide the true class and 
columns the predicted class (0: non-progression, 1: progression). (Note that for some patients with DFS times of 
up to 36 month the exact disease recurrence dates were not available and only the approximated DFS time of 36 
month could be used, leading to the event aggregation at 36 month in the plot.
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In this work, we presented a comprehensive introduction as well as a proof-of-principle application of the 
Tissue Phenomics approach for automatic phene discovery in prostate cancer. In particular, we demonstrated that 
tissue phenes with high prognostic value can be identified fully automatically based on few general assumptions 
such as the importance of immune cells for cancer evolution. Importantly, such phenes rely on mathematical 
relations of spatial distribution patterns of key immune players that would hardly have been possible to discover 
by manual inspection due to the large amount and high dimensionality of the data. Also, since the discovered 
phenes represent relations of objects from different IHC stains and measures derived by statistical evaluation 
within regions-of-interest which are not necessarily visible in every stain, such phenes typically cannot be seen 
directly by looking at the raw images. Using advanced image analysis methods for co-registration and segmenta-
tion we derived a large set of potential phenes. We ranked the phene candidates and selected a subset of phenes 
showing the highest prognostic value regarding tumor progression based on sound statistical evaluation. The 
selected phenes yield high accuracies of up to 83% regarding the uni-variate stratification of patients into disease 
progression groups. Although such phenes reflect nontrivial relationships of different players of the immune 
response they are interpretable and can be related to existing knowledge in the field. Combining the discovered 
phenes using machine learning techniques yields even higher accuracies of up to 88%. However, interpretation 
of the biological meaning is less intuitive for the resulting multi-variate models. An exception are decision trees 
where the outcome is obtained by iterating through a tree of subsequent decision rules similar as in many med-
ical decision making processes by clinicians. Thus, such classifiers might be easiest to communicate and to be 
accepted in clinical practice.
The most promising phenes identified in this study have been investigated regarding their biological plausi-
bility and turned out to agree well with previous findings as described in literature. For example, the top-ranking 
phene “RATIO #CD8_border1 TO #CD34_border1” (Table 2) suggests that a high ratio of areas of CD8(+) 
cells and CD34(+) microvessels in the tight tumor border are correlated with a good prognosis and long-term 
disease-free survival (for interpretation of the phene names see Table 3). This corresponds to high densities of 
CD8(+) cells and/or low microvessel densities, which as separate properties have been shown to be associated 
with good prognosis in prostate cancer in the literature: The hypothesis that CD34-based microvessel density is 
a significant predictive and prognostic factor is widely accepted and confirmed by various studies60,61, while the 
prognostic properties of tumor-infiltrating lymphocytes are more differentiated. Studies on general TIL density 
do not show a clear trend on whether high or low densities are beneficial62–66 since different subpopulations 
of effector and regulatory T lymphocytes are involved. However, high densities of tumor-infiltrating CD8(+) 
lymphocytes seem to be beneficial, being constructive mediators of an effective antitumor response67. The 
second-best phene “DIST CD68 TO CD34 IN nonIntact” which is also closely related to the 6th-ranked “RATIO 
#CD68_border2 TO #CD34_border1” as well includes the microvessel density in the tumor region, stating that 
larger distance of CD68(+) macrophages to microvessels or a high density of CD68(+) macrophages together 
with a low microvessel density point to a good prognosis. Again, a low microvessel density seems to be beneficial 
as well as a higher density of CD68(+) macrophages. For tumor-associated macrophages typically the CD68(+) 
M1-polarized phenotype is associated with tumor-suppressing properties indicating that a higher density of this 
population compared to the M2 type is beneficial65,68. On the contrary, high densities of CD163(+) M2-polarized 
macrophages are known to exhibit tumor-promoting behavior68–71. This corresponds well to the 4th-ranked phene 
“RATIO #CD8_nonIntact TO #CD163_nonIntact” where a high density of CD8(+) and importantly a low den-
sity CD163(+) relate to a good prognosis. Finally, also the mixture pattern of differently-sized non-cancerous 
and cancerous glands provides prognostic value as shown by the 3rd-ranked phene “CORR Haralick on intact & 
non-intact glands”. Here, a low linear dependency between glands of different types relates to cases without tumor 
progression. This to a certain degree reflects and refines the criteria used for Gleason scoring by systematically 
quantifying glandular patterns.
Current limitations of the prostate study include the moderate size of the study population (90 patients), the 
lack of an independent validation cohort from a different clinical site, as well as the limited length of the follow-up 
times for certain patients. In future work we are aiming to improve on these limitations, in particular, to test our 
findings on an additional patient cohort. Also, we will validate the prognostic phenes we identified in whole slide 
images from resected prostate tissue in fine needle biopsies. If similar patterns of the immunological landscape 
are observed also in needle biopsies Tissue Phenomics will directly improve critical treatment decision in pros-
tate cancer patients, for example, avoiding an unnecessary surgery, particularly in the case of intermediate risk 
patients. Finally, also in the context of immunotherapies Tissue Phenomics offers large potential to better stratify 
patients for the treatment options currently available for prostate cancer72.
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